NatureNews - Business - nature.com science feeds
Nature - the world's best science and medicine on your desktop
Tapping the crowd for technologies
Just how seriously is BP taking its own call for public solutions to the Gulf oil spill?
The lost legacy of the last great oil spill
Some ecosystems bounced back after the 1979 Ixtoc I oil spill, but research quickly withered.
US biotech firms line up for tax credits
Application process begins for cash to beat the downturn.
Food: Inside the hothouses of industry
Feeding the world is going to require the scientific and financial muscle of agricultural biotechnology companies. Natasha Gilbert asks whether they're up to the task.
Start-up model patently flawed
Study shows more US professors go into business as consultants than as inventors.
US seeks solar flair for fuels
Energy department launches initiative to commercialize artificial photosynthesis.
Journals step up plagiarism policing
Cut-and-paste culture tackled by CrossCheck software.
Strong medicine for French research
The medical-research adviser to France's president aims to shift power and money to universities.
Food: The global farm
With its plentiful sun, water and land, Brazil is quickly surpassing other countries in food production and exports. But can it continue to make agricultural gains without destroying the Amazon? Jeff Tollefson reports from Brazil.
White House stalls oil-slick research
Half-billion-dollar BP fund put on hold.
Strange lesions after stem-cell therapy
Unproven treatment results in mysterious masses.
Spanish science spending lockdown
Young researchers and new projects will take brunt of cuts.
Human genome at ten: Science after the sequence
The completion of the draft human genome sequence was announced ten years ago. Nature 's survey of life scientists reveals that biology will never be the same again. Declan Butler reports.
Fears over Europe's GM crop plan
A proposal to let nations opt out of growing European-approved GM varieties is under fire from all sides.
Consumer gene testing in the hotseat
A week of hearings sows uncertainty for the fledgling consumer genomics industry.
